country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P11591

Copy Link Print Information

PDI2

(Synonyms: PSMA-DOTA-PEI2)

Kundenbewertung

Based on 1 Customer Validation

PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.00%
CAS. Nr.: 3110124-60-9
Formel: C₅₉H₉₀N₁₂O₁₉
Molecular Weight:1271.41

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

PDI2 Chemical Structure

CAS. Nr.: 3110124-60-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Radionuclide-Drug Conjugates (RDCs) Isoform-spezifische Produkte anzeigen :

In Vitro

[¹¹¹In]In-PDI2 (0.195-50 nM; incubated on ice for 2 h) binds specifically to PSMA on LNCaP cells, with a K_d value of 22.8 nM^[1].
[¹¹¹In]In-PDI2 (37 kBq; incubated on ice for 2 h, incubated at 37°C for 0-4 h) shows an internalization rate of 38.9% in LNCaP cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PDI2 (111 kBq; i.v.; single dose) exhibits high and persistent tumor uptake in the PSMA-positive LNCaP prostate cancer xenograft model, along with a favorable tumor-to-kidney radioactivity ratio^[1].
PDI2 (5-10 kBq; i.v.; single dose) effectively inhibits the growth of PSMA-positive LNCaP prostate cancer xenografts with no obvious toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nu/nu (male, 5-6 weeks old)^[1]
Dosage:

111 kBq
Administration:

i.v.; single dose
Result:

Measured 20.74% ID/g tumor accumulation at 4-h postinjection; measured 25.47% ID/g tumor accumulation at 24-h postinjection; measured 13.54% ID/g tumor accumulation at 96-h postinjection; measured 52.31% ID/g renal uptake at 4-h postinjection; measured 4.85% ID/g renal uptake at 24-h postinjection; achieved 7.3 tumor-to-kidney radioactivity ratio.

Chemical Information

CAS. Nr. 3110124-60-9
Appearance Solid
Molecular Weight 1271.41
Formel C₅₉H₉₀N₁₂O₁₉
Color White to off-white
Synonyms

PSMA-DOTA-PEI2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 1 mg/mL (0.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hasegawa T, et al. Development of Novel Radiotheranostic Ligand with Positively Charged Unit Targeting Prostate-Specific Membrane Antigen. J Med Chem. 2025;68(10):10190-10202. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PDI2

Peptide Library

Alle Radionuclide-Drug Conjugates (RDCs) Isoform-spezifische Produkte anzeigen